Document Detail


Omega-3 Fatty acids: anti-arrhythmic, pro-arrhythmic, or both?
MedLine Citation:
PMID:  22529815     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
This review focuses on developments after 2008, when the topic was last reviewed by the author. Pertinent publications were found by medline searches and in the author's personal data base. Prevention of atrial fibrillation (AF) was investigated in a number of trials, sparked by one positive report on the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), considerations of upstream therapy, data from electrophysiologic laboratories and animal experiments. If EPA + DHA prevent postoperative AF, the effect is probably smaller than initially expected. The same is probably true for maintenance of sinus rhythm after cardioversion and for new-onset AF. Larger trials are currently ongoing. Prevention of ventricular arrhythmias was studied in carriers of an implanted cardioverter-defibrillator, with no clear results. This might have been due to a broad definition of the primary endpoint, including any ventricular arrhythmia and any action of the device. Epidemiologic studies support the contention that high levels of EPA + DHA prevent sudden cardiac death (SCD). However, since SCD is a rare occurrence, it is difficult to conduct an adequately powered trial. In patients with congestive heart failure, EPA + DHA reduced total mortality and rehospitalizations, but not SCD or presumed arrhythmic death. Of three trials in patients after a myocardial infarction, two were inadequately powered, and in one, the dose might have been too low. Taken together, while epidemiologic studies support an inverse relation between EPA + DHA and occurrence of SCD or arrhythmic death, demonstrating this effect in intervention trials remained elusive so far. A pro-arrhythmic effect of EPA + DHA has not been seen in intervention studies, and results of epidemiologic and animal studies also rather argue against such an effect. A different, and probably more productive, perspective is provided by a standardized analytical assessment of a person's status in EPA + DHA by use of the omega-3 index, EPA + DHA in red cell fatty acids. In populations with a high omega-3 index, SCD is rare. Intervention trials can become more effective by including a low omega-3 index into the inclusion criteria, thus creating a study population more likely to demonstrate an effect of EPA + DHA. This is especially relevant in case of rare endpoints, like new-onset AF or SCD.
Authors:
C von Schacky
Related Documents :
19950095 - Acute myocardial infarction in an 80 year-old woman caused by left main occlusion with ...
2210895 - Pharmacologic modifications of reperfusion arrhythmias in the dog in vivo: possible rel...
22806715 - Successful cryoablation of mahaim tachycardia in a child with ebstein's anomaly.
21801945 - Meta-analysis of organ damage after conversion from off-pump coronary artery bypass pro...
1383625 - Acute improvement of cardiac function with intravenous l-propionylcarnitine in humans.
18412505 - Numerical study of the uniformity of balloon-expandable stent deployment.
Publication Detail:
Type:  Journal Article     Date:  2012-04-17
Journal Detail:
Title:  Frontiers in physiology     Volume:  3     ISSN:  1664-042X     ISO Abbreviation:  Front Physiol     Publication Date:  2012  
Date Detail:
Created Date:  2012-04-24     Completed Date:  2012-10-02     Revised Date:  2013-08-13    
Medline Journal Info:
Nlm Unique ID:  101549006     Medline TA:  Front Physiol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  88     Citation Subset:  -    
Affiliation:
Preventive Cardiology, Medizinische Klinik and Poliklinik I, Ludwig Maximilians-University Munich Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Endocannabinoid-dopamine interactions in striatal synaptic plasticity.
Next Document:  Nerve-cancer interactions in the stromal biology of pancreatic cancer.